ClinicalTrials.gg
TerminatedNCT02484703Updated Jul 6, 2017

A Study of RO5186582 in Down Syndrome Among Children 6 to 11 Years of Age

A Phase 2 interventional study of Placebo and RO5186582 in Down Syndrome, sponsored by Hoffmann-La Roche. Terminated at 9 sites in United States. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2017-07-06.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Why this study was terminated
Study was terminated due to data from another study showing no efficacy. There were no safety issues of concern.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
6 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Down Syndrome by Hoffmann-La Roche — none open to participants now, none under way, none of them phase 3. Down Syndrome · Hoffmann-La Roche.

Started
2015
with 2 others
Phase 2
2 of 10
none open now
Registered
10th of 10
by date

Among the 10 studies in Down Syndrome by Hoffmann-La Roche, this one is one of 3 that started in 2015, is one of 2 in phase 2, and was the 10th registered.

Down Syndrome

439 studies on the registry are indexed under Down Syndrome; 100 are open to participants now.

Browse Down Syndrome studies →

Open to participants now

None of the 10 studies in Down Syndrome by Hoffmann-La Roche is open now. The open studies under Down Syndrome, anywhere →

Who these studies take

Of the 75 Down Syndrome studies recruiting now, 14 (19%) set no upper age limit and 58 (77%) stop at 75 or younger; 61 take children under 18; 19 take healthy volunteers.

This study: 6 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Down Syndrome by Hoffmann-La Roche as a file.
02

Study summary

This study will evaluate the safety, tolerability, efficacy, and pharmacokinetic and pharmacodynamic activity of 3 different dosages of RO5186582 compared with placebo. A total of approximately 46 participants will be enrolled, in order to have at least 32 evaluable, and will be randomly assigned to 1 of 4 treatments in a 1:1:1:1 ratio, with 9 children per treatment arm. The target ratio between 6-8 years and 9-11 years age groups is approximately 1:1 in each treatment arm, with a minimum of 3 children per age group in each treatment arm.

03

Conditions studied

  • Down Syndrome

Browse trials for

04

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Down syndrome, except for mosaic Down syndrome
  • Available parent or caregiver to attend clinic visits and provide information about the participant's behavior and symptoms

Exclusion criteria

Exclusion Criteria:

  • Any primary psychiatric comorbid disorder
  • History of infantile spasms, West syndrome, Lennox-Gastaut syndrome, early infantile epileptic encephalopathy, treatment- epilepsy with cognitive/developmental regression, severe head trauma, or central nervous system (CNS) infection
  • Seizure event of any type within 12 months prior to Screening or relevant changes in anti-epileptic drugs 6 weeks prior to enrollment
  • Significant sleep disruption
  • Significant gastrointestinal, renal, hepatic, endocrine, or cardiovascular disease
  • New-onset or ongoing hematologic/oncologic disorder
  • Severe lactose intolerance
  • Participation in another clinical study within 1 month or 6 half-lives prior to first dose, or any extent of participation in Study BP29589 (NCT02451657)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
45 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants will receive matching placebo by mouth (PO) twice daily (BID) for up to 26 weeks.

    Drug: Placebo

  • Experimental
    RO5186582 120 mg BID

    Participants will receive RO5186582 at a dosage of 120 milligrams (mg) PO BID for up to 26 weeks.

    Drug: RO5186582

  • Experimental
    RO5186582 40 mg BID

    Participants will receive RO5186582 at a dosage of 40 mg PO BID for up to 26 weeks.

    Drug: RO5186582

  • Experimental
    RO5186582 60 mg BID

    Participants will receive RO5186582 at a dosage of 60 mg PO BID for up to 26 weeks.

    Drug: RO5186582

Interventions

  • DrugPlacebo

    Participants will receive matching placebo PO BID. Study medication will first be administered on Day 1, and only the morning dose will be given on the last day of treatment (Week 26).

  • Participants will receive 1 of 3 dosages of RO5186582 PO BID, including 40 mg, 60 mg, or 120 mg. Study medication will first be administered on Day 1, and only the morning dose will be given on the last day of treatment (Week 26).

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events (AEs)

    Time frame: Baseline up to Week 6

  2. Percentage of Participants With Epileptiform Abnormalities as Assessed Using Electroencephalogram (EEG) Analysis

    Time frame: Baseline up to Week 6

  3. Percentage of Participants by Suicidality Classification as Assessed Using an Adapted Form of the Columbia Classification Algorithm for Suicide Assessment (C-CASA)

    Time frame: Baseline up to Week 6

  4. Anxiety, Depression, and Mood Scale (ADAMS) Score

    Time frame: Baseline up to Week 6

  5. Hyperactivity and Impulsivity as Assessed by the Short Version of Conners Third Edition Parent Short-Form (Conners-3) Score

    Time frame: Baseline up to Week 6

  6. Sleep Disturbances as Assessed by the Children's Sleep Habits Questionnaire (CSHQ) Score

    Time frame: Baseline up to Week 6

  7. Gamma Power at Posterior Electrodes as Assessed Using EEG Analysis

    Time frame: Baseline up to Week 6

  8. Theta Power at Posterior Electrodes as Assessed Using EEG Analysis

    Time frame: Baseline up to Week 6

  9. Cognition as Assessed by the Children's Memory Scale (CMS) Subtests Score

    Time frame: Baseline up to Week 6

Secondary outcomes

  1. Percentage of Participants With AEs

    Time frame: Baseline up to Week 26

  2. Percentage of Participants With Epileptiform Abnormalities as Assessed Using EEG Analysis

    Time frame: Baseline up to Week 26

  3. Percentage of Participants by Suicidality Classification as Assessed Using an Adapted Form of the C-CASA

    Time frame: Baseline up to Week 26

  4. ADAMS Score

    Time frame: Baseline up to Week 26

  5. Hyperactivity and Impulsivity as Assessed by the Short Version of Conners-3 Score

    Time frame: Baseline up to Week 26

  6. Sleep Disturbances as Assessed by the CSHQ Score

    Time frame: Baseline up to Week 26

  7. Gamma Power at Posterior Electrodes as Assessed Using EEG Analysis

    Time frame: Baseline up to Week 26

  8. Theta Power at Posterior Electrodes as Assessed Using EEG Analysis

    Time frame: Baseline up to Week 26

  9. Cognition as Assessed by the CMS Subtests Score

    Time frame: Baseline up to Week 26

  10. Adaptive Behavior as Assessed by the Vineland Adaptive Behavior Scales-II (VABS-II) Score

    Time frame: Baseline up to Week 26

  11. Clinical Global Impression-Improvement (CGI-I) Scale Score

    Time frame: Baseline up to Week 26

  12. Daily Functional Memory as Assessed by the Observer Memory Questionnaire-Parent Form (OMQ-PF) Score

    Time frame: Baseline up to Week 26

  13. Intellectual Quotient (IQ) as Assessed by the Leiter 3

    Time frame: Baseline up to Week 26

  14. Plasma Concentration of RO5186582

    Time frame: Predose (2 predose samples separated by at least 1 hour) at Weeks 2 and 6; and predose or postdose (as convenient) during Weeks 10, 17, and 26

07

Study locations

9 sites
  • Southwest Autism Research & Resource Center
    Phoenix, Arizona 85006, United States
  • Emory University School of Medicine; Department of Human Genetics & Pediatrics
    Decatur, Georgia 30033, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Massachusette General Hospital; Medical Genetics
    Boston, Massachusetts 02114, United States
  • Boston Children's Hospital, Department of Neurology
    Boston, Massachusetts 02115, United States
  • Duke Clin Rsch Institute
    Durham, North Carolina 27710, United States
  • UPMC Western Psychiatric Institute and Clinic
    Pittsburgh, Pennsylvania 15203 1101, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • University of Wisconsin Hospital and Clinics
    Madison, Wisconsin 53792, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2015 to primary completion in Aug 2016, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2015
First posted
Jun 30, 2015
StartActual
Oct 28, 2015
Primary completionActual
Aug 3, 2016
CompletionActual
Aug 3, 2016
Last update
Jul 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02484703
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 30, 2015
Start date
Oct 28, 2015
Primary completion
Aug 3, 2016
Completion
Aug 3, 2016
Last update
Jul 6, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Basmisanil

Start the discussion